Payment overview · 2025
General Payments
$291.55
8 reported records · 3 companies
Healthcare provider profile · identity verified
Manuel Borrego, MD
Allopathic & Osteopathic Physicians|Family Medicine · EL PASO, TX · NPI 1962510578
Verified facts
What the public records show
CMS Open Payments records show Manuel Borrego, MD received $291.55 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 87.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $254.67 | 87.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.11 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.77 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.55 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $128.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.87 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.87 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 948 | 374 |
| Metformin Hcl | Metformin Hcl | 721 | 268 |
| Levothyroxine Sodium | Levothyroxine Sodium | 664 | 240 |
| Lisinopril | Lisinopril | 614 | 231 |
| Losartan Potassium | Losartan Potassium | 519 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 177 |
| Gabapentin | Gabapentin | 434 | 161 |
| Simvastatin | Simvastatin | 417 | 159 |
| Alendronate Sodium | Alendronate Sodium | 375 | 132 |
| Fenofibrate | Fenofibrate | 372 | 139 |
| Ezetimibe | Ezetimibe | 349 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 138 |
| Glipizide | Glipizide | 284 | 104 |
| Zolpidem Tartrate | Zolpidem Tartrate | 265 | 61 |
| Carvedilol | Carvedilol | 261 | 99 |
| Alprazolam | Alprazolam | 256 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 107 |
| Finasteride | Finasteride | 236 | 91 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 219 | 96 |
| Omeprazole | Omeprazole | 215 | 94 |
| Meloxicam | Meloxicam | 209 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 80 |
| Glipizide Er | Glipizide | 200 | 76 |
| Baclofen | Baclofen | 178 | 76 |
| Furosemide | Furosemide | 176 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 66 |
| Tramadol Hcl | Tramadol Hcl | 167 | 60 |
| Ibuprofen | Ibuprofen | 158 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 76 |
| Sertraline Hcl | Sertraline Hcl | 141 | 60 |
| Montelukast Sodium | Montelukast Sodium | 130 | 57 |
| Prednisone | Prednisone | 128 | 97 |
| Trulicity | Dulaglutide | 128 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 123 | 75 |
| Azithromycin | Azithromycin | 122 | 101 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 121 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 119 | 38 |
| Jardiance | Empagliflozin | 117 | 37 |
| Dicyclomine Hcl | Dicyclomine Hcl | 109 | 53 |
| Eliquis | Apixaban | 106 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 91 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 34 |
| Azelastine Hcl | Azelastine Hcl | 85 | 44 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 82 | 28 |
| Ozempic | Semaglutide | 82 | 23 |
| Trazodone Hcl | Trazodone Hcl | 81 | 37 |
| Clonidine Hcl | Clonidine Hcl | 80 | 29 |
| Donepezil Hcl | Donepezil Hcl | 80 | 35 |
| Famotidine | Famotidine | 78 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 31 |
| Farxiga | Dapagliflozin Propanediol | 77 | 33 |
| Mirtazapine | Mirtazapine | 76 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 30 |
| Atenolol | Atenolol | 68 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 67 | 22 |
| Meclizine Hcl | Meclizine Hcl | 66 | 37 |
| Memantine Hcl | Memantine Hcl | 66 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 25 |
| Januvia | Sitagliptin Phosphate | 64 | 25 |
| Potassium Chloride | Potassium Chloride | 58 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 25 |
| Ondansetron Odt | Ondansetron | 56 | 32 |
| Spironolactone | Spironolactone | 54 | 22 |
| Buspirone Hcl | Buspirone Hcl | 51 | 22 |
| Lactulose | Lactulose | 51 | 31 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 50 | 30 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 30 |
| Cephalexin | Cephalexin | 47 | 18 |
| Celecoxib | Celecoxib | 46 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 17 |
| Naproxen | Naproxen | 46 | 24 |
| Allopurinol | Allopurinol | 45 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 32 |
| Eszopiclone | Eszopiclone | 42 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 42 | 14 |
| Sucralfate | Sucralfate | 42 | 16 |
| Telmisartan | Telmisartan | 42 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 12 |
| Nifedipine Er | Nifedipine | 36 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Pregabalin | Pregabalin | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 13 |
| Megestrol Acetate | Megestrol Acetate | 28 | 12 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 27 | 19 |
| Levofloxacin | Levofloxacin | 26 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 11 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | 12 |
| Loperamide | Loperamide Hcl | 23 | 15 |
| Metronidazole | Metronidazole | 23 | 12 |
| Linzess | Linaclotide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | 13 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 12 |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Promethegan | Promethazine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 12 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.55 · 8 records | Amgen Inc. | EVENITY, FREESTYLE LIBRE 3, OTEZLA, REPATHA, The Cologuard Plus Collection Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error